The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
|Articles|February 1, 2004
Use -59 modifier when billing for indwelling stent
Q I am in a multiple-physician urology practice. One of our physiciansbelieves that billing 52332 with 52352 or 52353 with a 59 modifiershould be paid, and that billing 52005 with 52332 with the 59 modifiershould be paid (ie, 52005-59). When is it appropriate to use the 59modifier?
Advertisement
Advertisement
Related to this article
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
2026 AUA/SUO NMIBC guideline: Key updates for clinical practice
3
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
4
AUA South Central Section Meeting: Mark D. Tyson, II, MD, MPH, recaps data in NMIBC
5